These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 26973244)

  • 1. Hypoxia and MITF regulate KIT oncogenic properties in melanocytes.
    Laugier F; Delyon J; André J; Bensussan A; Dumaz N
    Oncogene; 2016 Sep; 35(38):5070-7. PubMed ID: 26973244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A role for ATF2 in regulating MITF and melanoma development.
    Shah M; Bhoumik A; Goel V; Dewing A; Breitwieser W; Kluger H; Krajewski S; Krajewska M; Dehart J; Lau E; Kallenberg DM; Jeong H; Eroshkin A; Bennett DC; Chin L; Bosenberg M; Jones N; Ronai ZA
    PLoS Genet; 2010 Dec; 6(12):e1001258. PubMed ID: 21203491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inducibly decreased MITF levels do not affect proliferation and phenotype switching but reduce differentiation of melanoma cells.
    Vlčková K; Vachtenheim J; Réda J; Horák P; Ondrušová L
    J Cell Mol Med; 2018 Apr; 22(4):2240-2251. PubMed ID: 29369499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A common intronic variant of PARP1 confers melanoma risk and mediates melanocyte growth via regulation of MITF.
    Choi J; Xu M; Makowski MM; Zhang T; Law MH; Kovacs MA; Granzhan A; Kim WJ; Parikh H; Gartside M; Trent JM; Teulade-Fichou MP; Iles MM; Newton-Bishop JA; Bishop DT; MacGregor S; Hayward NK; Vermeulen M; Brown KM
    Nat Genet; 2017 Sep; 49(9):1326-1335. PubMed ID: 28759004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MITF controls the TCA cycle to modulate the melanoma hypoxia response.
    Louphrasitthiphol P; Ledaki I; Chauhan J; Falletta P; Siddaway R; Buffa FM; Mole DR; Soga T; Goding CR
    Pigment Cell Melanoma Res; 2019 Nov; 32(6):792-808. PubMed ID: 31207090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The phosphatidyl inositol 3-kinase pathway is central to the pathogenesis of Kit-activated melanoma.
    Liang R; Wallace AR; Schadendorf D; Rubin BP
    Pigment Cell Melanoma Res; 2011 Aug; 24(4):714-23. PubMed ID: 21595858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic analysis reveals the association of KIT and MITF variants with the white spotting in swamp buffaloes.
    Dai D; Sari EM; Si J; Ashari H; Dagong MIA; Pauciullo A; Lenstra JA; Han J; Zhang Y
    BMC Genomics; 2024 Jul; 25(1):713. PubMed ID: 39048931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An oncogenic role for ETV1 in melanoma.
    Jané-Valbuena J; Widlund HR; Perner S; Johnson LA; Dibner AC; Lin WM; Baker AC; Nazarian RM; Vijayendran KG; Sellers WR; Hahn WC; Duncan LM; Rubin MA; Fisher DE; Garraway LA
    Cancer Res; 2010 Mar; 70(5):2075-84. PubMed ID: 20160028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncogene-Expressing Senescent Melanocytes Up-Regulate MHC Class II, a Candidate Melanoma Suppressor Function.
    van Tuyn J; Jaber-Hijazi F; MacKenzie D; Cole JJ; Mann E; Pawlikowski JS; Rai TS; Nelson DM; McBryan T; Ivanov A; Blyth K; Wu H; Milling S; Adams PD
    J Invest Dermatol; 2017 Oct; 137(10):2197-2207. PubMed ID: 28647344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular and cellular pathogenesis of melanoma initiation and progression.
    Regad T
    Cell Mol Life Sci; 2013 Nov; 70(21):4055-65. PubMed ID: 23532409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GABA Regulates Electrical Activity and Tumor Initiation in Melanoma.
    Tagore M; Hergenreder E; Perlee SC; Cruz NM; Menocal L; Suresh S; Chan E; Baron M; Melendez S; Dave A; Chatila WK; Nsengimana J; Koche RP; Hollmann TJ; Ideker T; Studer L; Schietinger A; White RM
    Cancer Discov; 2023 Oct; 13(10):2270-2291. PubMed ID: 37553760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Analysis of Murine Kit
    Everdell E; Ji Z; Njauw CN; Tsao H
    JID Innov; 2024 May; 4(3):100266. PubMed ID: 38585193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dissecting melanocytes to predict melanoma.
    McConnell AM; Zon LI
    Nat Cell Biol; 2021 Sep; 23(9):930-931. PubMed ID: 34475537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MITF: More Interesting Traits, Folks!
    Kemper K; Krijgsman O; Peeper DS
    Pigment Cell Melanoma Res; 2016 May; 29(3):263-5. PubMed ID: 26999069
    [No Abstract]   [Full Text] [Related]  

  • 15. Microphthalmia-associated transcription factor suppresses invasion by reducing intracellular GTP pools.
    Bianchi-Smiraglia A; Bagati A; Fink EE; Moparthy S; Wawrzyniak JA; Marvin EK; Battaglia S; Jowdy P; Kolesnikova M; Foley CE; Berman AE; Kozlova NI; Lipchick BC; Paul-Rosner LM; Bshara W; Ackroyd JJ; Shewach DS; Nikiforov MA
    Oncogene; 2017 Jan; 36(1):84-96. PubMed ID: 27181209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Melanoma addiction to the long non-coding RNA SAMMSON.
    Leucci E; Vendramin R; Spinazzi M; Laurette P; Fiers M; Wouters J; Radaelli E; Eyckerman S; Leonelli C; Vanderheyden K; Rogiers A; Hermans E; Baatsen P; Aerts S; Amant F; Van Aelst S; van den Oord J; de Strooper B; Davidson I; Lafontaine DL; Gevaert K; Vandesompele J; Mestdagh P; Marine JC
    Nature; 2016 Mar; 531(7595):518-22. PubMed ID: 27008969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MITF Drives a Reversible Drug-Tolerant State in Melanoma.
    Cancer Discov; 2016 May; 6(5):OF11. PubMed ID: 27012829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance.
    Kaur A; Webster MR; Marchbank K; Behera R; Ndoye A; Kugel CH; Dang VM; Appleton J; O'Connell MP; Cheng P; Valiga AA; Morissette R; McDonnell NB; Ferrucci L; Kossenkov AV; Meeth K; Tang HY; Yin X; Wood WH; Lehrmann E; Becker KG; Flaherty KT; Frederick DT; Wargo JA; Cooper ZA; Tetzlaff MT; Hudgens C; Aird KM; Zhang R; Xu X; Liu Q; Bartlett E; Karakousis G; Eroglu Z; Lo RS; Chan M; Menzies AM; Long GV; Johnson DB; Sosman J; Schilling B; Schadendorf D; Speicher DW; Bosenberg M; Ribas A; Weeraratna AT
    Nature; 2016 Apr; 532(7598):250-4. PubMed ID: 27042933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy.
    Smith MP; Brunton H; Rowling EJ; Ferguson J; Arozarena I; Miskolczi Z; Lee JL; Girotti MR; Marais R; Levesque MP; Dummer R; Frederick DT; Flaherty KT; Cooper ZA; Wargo JA; Wellbrock C
    Cancer Cell; 2016 Mar; 29(3):270-284. PubMed ID: 26977879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of Type I Interferon Signaling Overcomes Oncogene-Induced Senescence and Mediates Melanoma Development and Progression.
    Katlinskaya YV; Katlinski KV; Yu Q; Ortiz A; Beiting DP; Brice A; Davar D; Sanders C; Kirkwood JM; Rui H; Xu X; Koumenis C; Diehl JA; Fuchs SY
    Cell Rep; 2016 Apr; 15(1):171-180. PubMed ID: 27052162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.